Colin Meyer Net Worth

The estimated Net Worth of Colin John Meyer is at least $42.6 Milion dollars as of 15 August 2023. Mr. Meyer owns over 2,740 units of Reata Pharmaceuticals Inc stock worth over $14,070,264 and over the last 8 years he sold RETA stock worth over $26,356,606. In addition, he makes $2,182,780 as Executive Vice President a Chief Research and Development Officer at Reata Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Meyer RETA stock SEC Form 4 insiders trading

Colin has made over 10 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,740 units of RETA stock worth $463,060 on 15 August 2023.

The largest trade he's ever made was selling 93,922 units of Reata Pharmaceuticals Inc stock on 2 March 2023 worth over $8,144,916. On average, Colin trades about 9,135 units every 101 days since 2016. As of 15 August 2023 he still owns at least 81,633 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Mr. Meyer stock trades at the bottom of the page.

Colin Meyer biography

Colin John Meyer M.D. serves as Executive Vice President, Chief Research and Development Officer of the Company. Dr. Meyer received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

What is the salary of Colin Meyer?

As the Executive Vice President a Chief Research and Development Officer of Reata Pharmaceuticals Inc, the total compensation of Colin Meyer at Reata Pharmaceuticals Inc is $2,182,780. There are 2 executives at Reata Pharmaceuticals Inc getting paid more, with Manmeet Soni having the highest compensation of $12,612,200.

How old is Colin Meyer?

Colin Meyer is 41, he's been the Executive Vice President a Chief Research and Development Officer of Reata Pharmaceuticals Inc since 2020. There are 15 older and no younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.

What's Colin Meyer's mailing address?

Colin's mailing address filed with the SEC is 5320 LEGACY DRIVE, , PLANO, TX, 75024.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy a Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.

What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Complete history of Mr. Meyer stock trades at Reata Pharmaceuticals Inc

Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Manmeet Soni,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• J. Warren Huff,
  Chairman of the Board, President, Chief Executive Officer
• Colin Meyer,
  Executive Vice President, Chief Research and Development Officer
• Michael Wortley,
  Executive Vice President, Chief Legal Officer
• Dawn Bir,
  Executive Vice President, Chief Commercial Officer
• Manmeet Singh Soni,
  COO, CFO & Pres
• J. Warren Huff,
  Chairman & CEO
• Dr. Colin J. Meyer M.D.,
  Exec. VP & Chief Innovation Officer
• Michael D. Wortley,
  Exec. VP & Chief Legal Officer
• Dawn Carter Bir,
  Exec. VP & Chief Commercial Officer
• Jack Nielsen,
  Independent Director
• William McClellan,
  Independent Director
• William Rose,
  Independent Director
• R. Kent McGaughy,
  Independent Director
• Vineet Jindal,
  Vice President, Corporate Communications and Strategy
• Martin Edwards,
  Independent Director
• Seemi Khan,
  Chief Medical Officer
• Andrea Loewen,
  Vice President - Global Regulatory Affairs
• Kevin Johnston,
  Chief Technical Officer, Vice President
• Steve Harman,
  VP & Chief HR Officer
• Dakota Gallivan,
  VP & Chief Healthcare Compliance Officer
• Dr. W. Christian Wigley Ph.D.,
  Sr. VP & Chief Scientific Officer
• Bhaskar Anand,
  VP & Chief Accounting Officer
• William Puffin Partners, L....,
  
• Dennis K. Stone,
  Director
• Elaine Castellanos,
  VP, Chief Accounting Officer
• Holdings A/S Novo,
  10% owner
• James Edward Bass,
  Director
• James W Jr Traweek,
  
• Inc Cpmg,
  
• Inc. Abb Vie,
  10% owner
• Keith Wayne Ward,
  See Remarks
• William Rose Evelyn P.Edwar...,
  
• William Puffin Partners, L....,
  
• Antal Rohit Cpmg Inc Desai,
  
• William Montrose Investment...,
  
• William Charles Henry Rose ...,
  
• William Puffin Partners, L....,
  
• William Estate Of Edward W....,
  
• Jason Douglas Wilson,
  Executive VP of Operations
• Pharma Llcstapleton Craig R...,
  
• Christy J. Oliger,
  Director
• Shamim Ruff,
  Director
• Bhaskar Anand,
  SVP, Chief Accounting Officer
• Steven Ryder,
  Director
• Samina Khan,
  SVP, Chief Medical Officer
• Rajiv Patni,
  EVP, Chief R&D Officer